GLP-1 Medication Pricing Guide

Lowest cash-pay price at a glance

If you need to pay out of pocket, here is the lowest manufacturer-supported cash-pay option for each medication as of March 26, 2026. When a manufacturer does not list a separate uninsured cash-pay program, we note that instead of quoting a single retail pharmacy price.

Wegovy (semaglutide) — Novo Nordisk

Wegovy is FDA-approved for chronic weight management and is available as both an injection pen and an oral tablet. Novo Nordisk offers several self-pay pricing tiers depending on the form factor and dosage.

Source: NovoCare / wegovy.com. New self-pay patients pay $199/month for the first two monthly fills of 0.25 mg and 0.5 mg between November 17, 2025 and June 30, 2026. After that, eligible self-pay patients pay $349/month for injection doses.

Source: Wegovy.com / NovoCare. Official Wegovy pricing pages currently list tablet pricing for 1.5 mg, 4 mg, 9 mg, and 25 mg doses, with limited-time introductory pricing on the 1.5 mg and 4 mg strengths.

For details on the Wegovy savings card for commercially insured patients, see our Wegovy Savings Card guide.

Zepbound (tirzepatide) — Eli Lilly

Zepbound is FDA-approved for chronic weight management. Eli Lilly sells single-dose vials directly to patients through LillyDirect at prices significantly below the list price for injection pens.

Source: LillyDirect self-pay Journey program terms and Lilly pricing pages. Higher doses are $449/month when refilled within 45 days. Current Lilly terms list regular prices of $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg if the Journey offer does not apply.

For details on the Zepbound savings card for commercially insured patients, see our Zepbound Savings Program guide.

Ozempic (semaglutide) — Novo Nordisk

Ozempic is FDA-approved for type 2 diabetes, not weight management. Some providers prescribe it off-label for weight loss. Insurance coverage for weight loss use is typically more limited than for Wegovy.

Source: NovoCare / ozempic.com, GoodRx. The $199/mo introductory self-pay offer is available through June 30, 2026 for the two lowest doses. Novo Nordisk also offers a Patient Assistance Program (PAP) for uninsured patients with qualifying income.

For details on the Ozempic savings card, see our Ozempic Savings Card guide.

Mounjaro (tirzepatide) — Eli Lilly

Mounjaro is FDA-approved for type 2 diabetes and contains the same active ingredient (tirzepatide) as Zepbound. All dosage strengths are priced identically at the manufacturer level.

Source: mounjaro.lilly.com and pricinginfo.lilly.com. Lilly currently directs patients without commercial drug insurance to check pharmacy pricing and support options; if you are not eligible for the Mounjaro Savings Program, you may have to pay close to list price. LillyDirect single-dose vials are currently available for Zepbound but not Mounjaro.

For details on the Mounjaro savings card, see our Mounjaro Savings Card guide.

Savings programs at a glance

Each manufacturer offers programs to help reduce out-of-pocket costs. Eligibility and terms differ between the two companies.

How PEAK helps with cost

PEAK does not sell medications directly, but our team works to make sure every patient gets the lowest cost available to them. Here is what happens when you start treatment:

• We verify your insurance benefits and check for GLP-1 coverage before your first visit.
• We handle prior authorization and appeals if your plan requires them.
• We help you enroll in manufacturer savings cards and patient assistance programs.
• If you are paying out of pocket, we walk you through the lowest-cost options for your specific medication and dose.

For a full breakdown of PEAK visit costs (separate from medication pricing), see our Weight Loss Program Cost page.